

Document control sheet

GUIDELINE NUMBER	
AREA IN WHICH THIS MONOGRAPH APPLIES	NEONATAL UNIT

DIVISIONAL AUTHORISATION	
GROUP	DATE
Paediatric monograph review group	13.04.2022
Clinical Director – Paediatric BU	
Divisional Clinical Governance Committee – Integrated care	

AUTHORS		
Author	Position	Date
Written by: Harriet Hughes	Advanced Pharmacist, Women's and Children's	12.11.20
Checked by: Naomi Gladwell	Specialist Pharmacist, Women's and Children's	02.03.2022

If review:

	Position	Date
Reviewed by: Name		
Checked by: Name		

Change history:

Changes Reference	Change details	Date

NICU: Intravenous Paracetamol

Presentation:	Paracetamol 500mg/50mL (10mg/mL) solution for infusion																																						
Indication:	Pain/Pyrexia where oral route not tolerated/appropriate, Closure of PDA																																						
Dose:	<p>For dosing, use corrected gestational age (CGA)</p> <p>Indication: Pain/Pyrexia where oral route not tolerated/appropriate</p> <table border="1"> <tr> <td rowspan="2">Preterm</td> <td><32 weeks CGA</td> <td rowspan="3">7.5mg/kg</td> <td>12 hourly</td> <td colspan="2">Max daily dose: 15mg/kg/day</td> </tr> <tr> <td>32⁺⁰ – 36⁺⁶ CGA</td> <td>8 hourly</td> <td colspan="2">Max daily dose: 22.5mg/kg/day</td> </tr> <tr> <td>Term</td> <td>≥ 37 weeks to 44 weeks*</td> <td>6 hourly</td> <td colspan="2">Max daily dose: 30mg/kg/day</td> </tr> </table> <p><i>*Higher doses of 10mg/kg can be given in term babies, but the 24-hour daily maximum dose remains the same.</i></p> <p>Indication: Closure of PDA [see additional comments]</p> <table border="1"> <tr> <td>23⁺⁰ – 25⁺⁶ weeks CGA AND ≤ 7 days old</td> <td>LOAD</td> <td>20mg/kg</td> <td>Maintenance</td> <td>12.5mg/kg</td> <td>6 hourly</td> </tr> <tr> <td>23⁺⁰ – 25⁺⁶ weeks CGA AND > 7 days old</td> <td>LOAD</td> <td>20mg/kg</td> <td>Maintenance</td> <td>15mg/kg</td> <td>6 hourly</td> </tr> <tr> <td>≥ 26 weeks CGA</td> <td>LOAD</td> <td>20mg/kg</td> <td>Maintenance</td> <td>15mg/kg</td> <td>6 hourly</td> </tr> </table> <p>PDA closure: Course length range between 2-7 days, typically in practice 3 days.</p> <p>Monitoring: Check paracetamol [red-top bottle] level immediately <u>before giving the third maintenance dose</u>. Desired level 15-25 mg/mL. Where levels are within range, continue with regimen. If course > 3 days, recheck levels on alternate days. Check LFT's daily. If liver toxicity suspected (INR>1.5 or LFTs > 3 x baseline) withhold the dose and check paracetamol level 4 hours after the dose was administered. Where paracetamol level is ≥25mg/dL, stop therapy.</p>						Preterm	<32 weeks CGA	7.5mg/kg	12 hourly	Max daily dose: 15mg/kg/day		32 ⁺⁰ – 36 ⁺⁶ CGA	8 hourly	Max daily dose: 22.5mg/kg/day		Term	≥ 37 weeks to 44 weeks*	6 hourly	Max daily dose: 30mg/kg/day		23 ⁺⁰ – 25 ⁺⁶ weeks CGA AND ≤ 7 days old	LOAD	20mg/kg	Maintenance	12.5mg/kg	6 hourly	23 ⁺⁰ – 25 ⁺⁶ weeks CGA AND > 7 days old	LOAD	20mg/kg	Maintenance	15mg/kg	6 hourly	≥ 26 weeks CGA	LOAD	20mg/kg	Maintenance	15mg/kg	6 hourly
Preterm	<32 weeks CGA	7.5mg/kg	12 hourly	Max daily dose: 15mg/kg/day																																			
	32 ⁺⁰ – 36 ⁺⁶ CGA		8 hourly	Max daily dose: 22.5mg/kg/day																																			
Term	≥ 37 weeks to 44 weeks*		6 hourly	Max daily dose: 30mg/kg/day																																			
23 ⁺⁰ – 25 ⁺⁶ weeks CGA AND ≤ 7 days old	LOAD	20mg/kg	Maintenance	12.5mg/kg	6 hourly																																		
23 ⁺⁰ – 25 ⁺⁶ weeks CGA AND > 7 days old	LOAD	20mg/kg	Maintenance	15mg/kg	6 hourly																																		
≥ 26 weeks CGA	LOAD	20mg/kg	Maintenance	15mg/kg	6 hourly																																		
Route of administration:	<p>Intravenous</p> <p>Infusion time: Give over 15 minutes</p>																																						
Instructions for preparation:	<p>Order a 500mg/50mL solution for infusion from Pharmacy</p> <p>Withdraw the required dose from a 500mg in 50mL preparation into a syringe and administer using a Syramed infusion pump.</p> <p>E.g. If you have a 2.5kg 36⁺¹ week gestation baby 7.5mg x 2.5kg = 18.75mg (dose prescribed = 18mg)</p> <p>You have a 500mg/50mL (10mg/mL) solution; therefore withdraw the dose 18mg [1.8mL] + overage from the solution.</p> <p>If needed, to aid administration consider withdrawing the volume to be administered and further diluting with sodium chloride 0.9% or glucose 5% to a minimum concentration of 1mg in 1mL. The diluted solution should be used immediately but if this is not possible the expiry time of the diluted solution should be limited to one hour (including infusion time).</p>																																						
Prescribing	Prescribe on paper drug chart as per Trust prescribing policy																																						
SMART pump directions	Use emergency drug setting																																						

Known compatibility issues	Compatible: Fentanyl, Morphine, Hydrocortisone, Potassium Chloride, Vancomycin, Midazolam. Incompatible: Aciclovir
Additional Comments:	<p>NB. IV paracetamol is not licensed in pre-term neonates</p> <p>Avoid large doses in liver impairment. Use with care in babies on other drugs affecting the liver. Neonates may be more susceptible to paracetamol induced liver toxicity, therefore treatment with N-acetylcysteine should be considered in all paracetamol overdoses.</p> <p>NB. Caution where babies are dependent on maintaining patency of ductus arteriosus, as paracetamol may close PDA.</p> <p>Paracetamol clearance is lower in neonates than in children and adults. After metabolic conversion, paracetamol is subsequently eliminated by the renal route.</p> <p>Paracetamol appears to be a promising alternative to indomethacin and ibuprofen for the closure of a PDA with possibly fewer adverse effects. Additional studies testing this intervention and including longer-term follow-up are needed before paracetamol can be recommended as standard treatment for a PDA in preterm infants.</p>

Note: The contents of this monograph should be read in conjunction with information available in the BNFC and Medusa

References:

NUH NICU Pharmacopoeia Paracetamol monograph, accessed via www.nuh.nhs.uk on 12.11.20

British National Formulary for Children, accessed via www.medicinescomplete.com on 16.06.21

Medusa Injectable Medicines Guide, accessed via <http://medusa.wales.nhs.uk> on 12.11.20

Trissel LA (Ed), Handbook on Injectable Drugs, accessed via www.medicinescomplete.com on 12.11.20

Pacifici, Gian Maria, and Karel Allegaert. "Clinical pharmacology of paracetamol in neonates: a review." *Current therapeutic research, clinical and experimental* vol. 77 24-30. 12 Dec. 2014, doi:10.1016/j.curtheres.2014.12.001 accessed on 12.11.20

Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. *Cochrane Database of Systematic Reviews* 2020, Issue 1. Art. No.: CD010061. DOI: 10.1002/14651858.CD010061.pub4

Mitra S, Florez ID, Tamayo ME, et al: Association of placebo, indomethacin, ibuprofen, and acetaminophen with closure of hemodynamically significant patent ductus arteriosus in preterm infants: a systematic review and meta-analysis. *JAMA* 2018; 319(12):1221-1238.

Tekgündüz, K., Ceviz, N., Caner, İ, Olgun, H., Demirelli, Y., Yolcu, C., . . . Kara, M. (2015). Intravenous paracetamol with a lower dose is also effective for the treatment of patent ductus arteriosus in pre-term infants. *Cardiology in the Young*, 25(6), 1060-1064. doi:10.1017/S1047951114001577

Neonatal Formulary, Eighth Edition, Page 602-603, Paracetamol.

Evelina London Paediatric Formulary, Paracetamol. Last accessed 16.06.21